Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 8
2003 4
2004 5
2005 5
2006 6
2007 9
2008 10
2009 8
2010 9
2011 5
2012 6
2013 3
2014 5
2015 9
2016 11
2017 5
2018 3
2019 4
2020 10
2021 15
2022 6
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L, Wehbe M, Pastora LE, Yang J, Kimmel BR, Garland KM, Becker KW, Carson CS, Roth EW, Gibson-Corley KN, Ulkoski D, Krishnamurthy V, Fedorova O, Richmond A, Pyle AM, Wilson JT. Wang-Bishop L, et al. Among authors: richmond a. ACS Nano. 2024 Apr 23. doi: 10.1021/acsnano.3c06225. Online ahead of print. ACS Nano. 2024. PMID: 38652829
Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.
Bullock KK, Shattuck-Brandt R, Scalise C, Luo W, Chen SC, Saleh N, Gonzalez-Ericsson PI, Garcia G, Sanders ME, Ayers GD, Yan C, Richmond A. Bullock KK, et al. Among authors: richmond a. Cancer Lett. 2024 Apr 1;586:216681. doi: 10.1016/j.canlet.2024.216681. Epub 2024 Feb 3. Cancer Lett. 2024. PMID: 38311054 Free article.
Harnessing the potential of CD40 agonism in cancer therapy.
Zhou Y, Richmond A, Yan C. Zhou Y, et al. Among authors: richmond a. Cytokine Growth Factor Rev. 2024 Feb;75:40-56. doi: 10.1016/j.cytogfr.2023.11.002. Epub 2023 Dec 4. Cytokine Growth Factor Rev. 2024. PMID: 38102001 Free article. Review.
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Kumar A, Ramani V, Bharti V, de Lima Bellan D, Saleh N, Uzhachenko R, Shen C, Arteaga C, Richmond A, Reddy SM, Vilgelm A. Kumar A, et al. Among authors: richmond a. J Immunother Cancer. 2023 May;11(5):e006019. doi: 10.1136/jitc-2022-006019. J Immunother Cancer. 2023. PMID: 37230537 Free PMC article.
BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.
Bharti V, Watkins R, Kumar A, Shattuck-Brandt RL, Mossing A, Mittra A, Shen C, Tsung A, Davies AE, Hanel W, Reneau JC, Chung C, Sizemore GM, Richmond A, Weiss VL, Vilgelm AE. Bharti V, et al. Among authors: richmond a. Cell Rep. 2022 Dec 20;41(12):111826. doi: 10.1016/j.celrep.2022.111826. Cell Rep. 2022. PMID: 36543138 Free PMC article.
138 results